Literature DB >> 24452629

Mutually exclusive mutations of KIT and RAS are associated with KIT mRNA expression and chromosomal instability in primary intracranial pure germinomas.

Shintaro Fukushima1, Ayaka Otsuka, Tomonari Suzuki, Takaaki Yanagisawa, Kazuhiko Mishima, Akitake Mukasa, Nobuhito Saito, Toshihiro Kumabe, Masayuki Kanamori, Teiji Tominaga, Yoshitaka Narita, Soichiro Shibui, Mamoru Kato, Tatsuhiro Shibata, Masao Matsutani, Ryo Nishikawa, Koichi Ichimura.   

Abstract

Intracranial germ cell tumors (iGCTs) are the second most common brain tumors among children under 15 in Japan. The pathogenesis of iGCTs is largely unexplored. Although a subset of iGCTs is known to have KIT mutation, its impact on the biology and patients' survival has not been established. In this study, we investigated genes involved in the KIT signaling pathway. 65 iGCTs (30 pure germinomas, 14 teratomas, 18 mixed GCTs, 2 yolk sac tumors, 1 choriocarcinoma) were screened for mutation of KIT, KRAS, NRAS, HRAS, BRAF, PDGFRA, and IDH1 by direct sequencing. KIT expression was examined by immunohistochemistry and quantitative PCR. Chromosomal status was analyzed by array-comparative genomic hybridization (aCGH). Somatic mutations were detected only in KIT and RAS, which were frequently observed in pure germinomas (60.0 %), but rare in non-germinomatous GCTs (NGGCTs) (8.6 %). All KIT/RAS mutations were mutually exclusive. Regardless of the mutation status or mRNA expression, the KIT protein was expressed in all germinomas, while only in 54.3 % of NGGCTs. Amplification of KIT was found in one pure germinoma by aCGH. In pure germinomas, high expression of KIT mRNA was associated with the presence of KIT/RAS alterations and severe chromosomal instability. Our results indicate that alterations of the KIT signaling pathway play an important role in the development of germinomas. Pure germinomas may develop through two distinct pathogeneses: one with KIT/RAS alterations, elevated KIT mRNA expression and severe chromosomal instability, and the other through yet an unidentified mechanism without any of the above abnormalities.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24452629     DOI: 10.1007/s00401-014-1247-5

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  23 in total

1.  Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT Consortium.

Authors:  Hirokazu Takami; Kohei Fukuoka; Shintaro Fukushima; Taishi Nakamura; Akitake Mukasa; Nobuhito Saito; Takaaki Yanagisawa; Hideo Nakamura; Kazuhiko Sugiyama; Masayuki Kanamori; Teiji Tominaga; Taketoshi Maehara; Mitsutoshi Nakada; Yonehiro Kanemura; Akio Asai; Hideo Takeshima; Yuichi Hirose; Toshihiko Iuchi; Motoo Nagane; Koji Yoshimoto; Akira Matsumura; Kazuhiko Kurozumi; Hiroyuki Nakase; Keiichi Sakai; Tsutomu Tokuyama; Soichiro Shibui; Yoichi Nakazato; Yoshitaka Narita; Ryo Nishikawa; Masao Matsutani; Koichi Ichimura
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 12.300

2.  Human chorionic gonadotropin is expressed virtually in all intracranial germ cell tumors.

Authors:  Hirokazu Takami; Shintaro Fukushima; Kohei Fukuoka; Tomonari Suzuki; Takaaki Yanagisawa; Yuko Matsushita; Taishi Nakamura; Hideyuki Arita; Akitake Mukasa; Nobuhito Saito; Masayuki Kanamori; Toshihiro Kumabe; Teiji Tominaga; Keiichi Kobayashi; Motoo Nagane; Toshihiko Iuchi; Kaoru Tamura; Taketoshi Maehara; Kazuhiko Sugiyama; Mitsutoshi Nakada; Yonehiro Kanemura; Masahiro Nonaka; Kiyotaka Yokogami; Hideo Takeshima; Yoshitaka Narita; Soichiro Shibui; Yoichi Nakazato; Ryo Nishikawa; Koichi Ichimura; Masao Matsutani
Journal:  J Neurooncol       Date:  2015-05-21       Impact factor: 4.130

3.  Pineal region tumors: a simplified management scheme.

Authors:  Mohamed A Zaazoue; Liliana C Goumnerova
Journal:  Childs Nerv Syst       Date:  2016-07-30       Impact factor: 1.475

4.  Global DNA methylation analysis reveals miR-214-3p contributes to cisplatin resistance in pediatric intracranial nongerminomatous malignant germ cell tumors.

Authors:  Tsung-Han Hsieh; Yun-Ru Liu; Ting-Yu Chang; Muh-Lii Liang; Hsin-Hung Chen; Hsei-Wei Wang; Yun Yen; Tai-Tong Wong
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

5.  Intracranial germinomas in a father and his son.

Authors:  Kampei Shimizu; Yohei Mineharu; Hirotoshi Imamura; Katsunori Asai; Yukihiro Imai; Koichi Ichimura; Nobuyuki Sakai
Journal:  Childs Nerv Syst       Date:  2014-06-07       Impact factor: 1.475

Review 6.  Management of CNS germinoma.

Authors:  Diana S Osorio; Jeffrey C Allen
Journal:  CNS Oncol       Date:  2015-06-29

7.  Preservation of KIT genotype in a novel pair of patient-derived orthotopic xenograft mouse models of metastatic pediatric CNS germinoma.

Authors:  Holly Lindsay; Yulun Huang; Yuchen Du; Frank K Braun; Wan Yee Teo; Mari Kogiso; Lin Qi; Huiyuan Zhang; Sibo Zhao; Hua Mao; Frank Lin; Patricia Baxter; Jack M Su; Keita Terashima; Laszlo Perlaky; Murali Chintagumpala; Adekunle Adesina; Ching C Lau; D Williams Parsons; Xiao-Nan Li
Journal:  J Neurooncol       Date:  2016-03-08       Impact factor: 4.130

8.  EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors.

Authors:  Kenneth S Chen; Nicholas J Fustino; Abhay A Shukla; Emily K Stroup; Albert Budhipramono; Christina Ateek; Sarai H Stuart; Kiyoshi Yamaguchi; Payal Kapur; A Lindsay Frazier; Lawrence Lum; Leendert H J Looijenga; Theodore W Laetsch; Dinesh Rakheja; James F Amatruda
Journal:  Mol Cancer Ther       Date:  2018-02-26       Impact factor: 6.261

9.  Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial.

Authors:  Gabriele Calaminus; Didier Frappaz; Rolf Dieter Kortmann; Barbara Krefeld; Frank Saran; Torsten Pietsch; Alexandre Vasiljevic; Maria Luisa Garre; Umberto Ricardi; Jillian R Mann; Ulrich Göbel; Claire Alapetite; Matthew J Murray; James C Nicholson
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

10.  Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

Authors:  Catherine A Eberlein; Daniel Stetson; Aleksandra A Markovets; Katherine J Al-Kadhimi; Zhongwu Lai; Paul R Fisher; Catherine B Meador; Paula Spitzler; Eiki Ichihara; Sarah J Ross; Miika J Ahdesmaki; Ambar Ahmed; Laura E Ratcliffe; Elizabeth L Christey O'Brien; Claire H Barnes; Henry Brown; Paul D Smith; Jonathan R Dry; Garry Beran; Kenneth S Thress; Brian Dougherty; William Pao; Darren A E Cross
Journal:  Cancer Res       Date:  2015-04-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.